| ||||||||||||||||
| ||||||||||||||||
— Pfizer —Top tagsYou have executed a tag search on The Deal Newsweekly. To the right you will find a comprehensive list of stories tagged "Pfizer." Below are the most-popular tags for The Deal Newsweekly. On the right of the page you will find a search box to dig deeper into our content.
Community
 Entries tagged "Pfizer"Big PharmaPfizer-Wyeth, Merck-Schering Plough. 2009 has seen some big-ticket pharma deals. Scenes from the slowdownM&A activity may have stalled during the first half of the year, but deal lawyers still had plenty to talk about. Morphing modelsA conversation with former Pfizer, now University of California, San Francisco, biotech veteran Corey Goodman. Deep cleansing treatmentAs Pfizer prepares for another digestive challenge in the form of Wyeth, it is trying to unload some compounds it already has. Promoting healthy dealflowHow contingent value rights bridge gaps between buyers and sellers in the healthcare industry. The marriage of theory and practiceAbigail Barrow and Steven Shapin on the interaction of science, technology and economic development. That's a spicy meatballSkepticism abounds over Pfizer's ability to digest Wyeth. Movers & shakers: March 30, 2009Nomura Holdings Inc. hired Andrea Pellegrini as co-chairman for Italy and head of investment banking, partnering with Alessandro Cremona, chairman of investment banking for Italy.... A whole new ballgameRecent big-ticket pharma deals illustrate the evolution of financing outs and breakup fees. Paging Dr. SchollThe consumer-products subplot in the pharmaceutical megamergers. Little pharma bluesAs the economy foundered, drug industry insiders looked forward to an M&A frenzy. But with a few exceptions, deals occurred only at the top of the food chain. Merck, Schering play follow the pharmaDamian Ridealgh and other Fried Frank attorneys advised Merck on its deal for Schering. The big trialFrom VC to licensing, Exelixis has done every kind of deal to keep itself afloat, except one. Is an acquisition next? Exit papersWhen Mars signed a deal to buy Wrigley, it reserved the right to skip out. That has since become the industry standard. Dead, temporarilyThe media's decided that Wall Street is definitely kaput. Trying to figure what's there instead is more of a problem. Critical, if improvingSome financing markets are open, others are closed. The future remains desperately uncertain, but at least the patient shows signs of life. Surprise!For sheer drama, Roche's hostile, discounted bid for Genentech tops even Pfizer's bid for Wyeth. Pfizer taps Cadwalader for Wyeth adviceMost noteworthy in the $68B deal may be the size of the reverse termination fee: $4.5B. Mood enhancersDrug companies get a warm reception in the debt market these days. Risk Arbitrage: Feb. 9, 20092009 has begun better than it might have on the M&A front. Transactions: Feb. 9, 2009In the boom, a bewildering number of markets seemed to merge to one Metamarket. Now that it's all fractured, putting it back together is quite a chore. Abbott leads the biotech waveSkadden's Brian McCarthy led a team advising AMO in its sale to Abbott Labs. They need a new drugExpect Big Pharma to go shopping in biotechland, but with an eye for fire sales. Cravath helps J&J implant Mentor, OmrixJ&J's Mentor deal grew out of a realization during the Beijing Olympics of the market potential for cosmetic products in Asia. This won't hurt a bitAn examination of U.S. healthcare under the Obama administration. The Supreme questionDoes the FDA trump the states? Ad addFor years Japan's largest agency has tried to expand into the U.S., and now it tries again, buying a hot New York firm in a tough M&A market. Bridge over troubled watersCalifornia's stem cell institute has money to lend to biotech startups and, it hopes, lure VCs to the table. ImCloneMassachusetts' State-Boston Pension Fund has stepped in with a lawsuit to block Eli Lilly's $6.5 billion deal for ImClone. Risk Arb updateUncertainty in banking and M&A credit markets have hammered share prices of targets of hostile bids, along with the broader stock market. A seller's marketUniversities are getting in on pharma royalty deals. Litigation riskFASB weighs requiring companies to estimate their exposure to legal damages; business tries to bury the idea. Truthiness in holdingsCompanies are now crafting bylaws designed to flush out the actual size of activist stakes. The incredible shrinking middlemanThe question of hiring an agent hovers over biotechs seeking partners or buyers among Japanese pharmas. | ||||||||||||||||
|
|
|
|
|
